drugset / Trial / NCT03576690

R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease

NCT03576690

Expanded access Available Regeneron Pharmaceuticals

Summary

Provide access to REGN-EB3 for the treatment of patients with Ebola Virus Disease (EVD).

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Inmazeb Monoclonal antibody